Ranger Investment Management L.P. Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Ranger Investment Management L.P. bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 343,150 shares of the specialty pharmaceutical company’s stock, valued at approximately $28,406,000. ANI Pharmaceuticals comprises about 1.8% of Ranger Investment Management L.P.’s portfolio, making the stock its 17th largest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares during the last quarter. Jane Street Group LLC purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at about $2,706,000. Finally, Norges Bank bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $625,000. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the transaction, the vice president owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at approximately $15,268,698. The trade was a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 18,987 shares of company stock valued at $1,546,405. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $75.35 on Monday. The business’s 50 day simple moving average is $80.36 and its 200-day simple moving average is $78.88. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 16.24 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Canaccord Genuity Group decreased their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.